Search Results
You are looking at 1 - 4 of 4 items for
- Author: Carla Colombo x
- Refine by access: All content x
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Marina Muzza in
Google Scholar
PubMed
Search for other papers by Gabriele Pogliaghi in
Google Scholar
PubMed
Search for other papers by Sonia Palazzo in
Google Scholar
PubMed
Search for other papers by Guia Vannucchi in
Google Scholar
PubMed
Search for other papers by Leonardo Vicentini in
Google Scholar
PubMed
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Search for other papers by Giacomo Gazzano in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Cytology is the gold standard method for the differential diagnosis of thyroid nodules, though 25–30% of them are classified as indeterminate. We aimed to set up a ‘thyroid risk score’ (TRS) to increase the diagnostic accuracy in these cases. We prospectively tested 135 indeterminate thyroid nodules. The pre-surgical TRS derived from the sum of the scores assigned at cytology, EU-TIRADS classification, nodule measurement, and molecular characterization, which was done by our PTC-MA assay, a customized array able to cost-effectively evaluate 24 different genetic alterations including point mutations and gene fusions. The risk of malignancy (ROM) increased paralleling the score: in the category >4 and ≤ 6 (low suspicion), >6 ≤ 8 (intermediate suspicion), and >8 (high suspicion); ROM was 10, 47 and 100%, respectively. ROC curves selected the score >6.5 as the best threshold to differentiate between malignant and benign nodules (P < 0.001). The TRS > 6.5 had a better performance than the single parameters evaluated separately, with an accuracy of 77 and 82% upon inclusion of noninvasive follicular thyroid neoplasm with papillary-like nuclear features among malignant or benign cases, respectively. In conclusion, for the first time, we generated a score combining a cost-effective molecular assay with already validated tools, harboring different specificities and sensitivities, for the differential diagnosis of indeterminate nodules. The combination of different parameters reduced the number of false negatives inherent to each classification system. The TRS > 6.5 was highly suggestive for malignancy and retained a high accuracy in the identification of patients to be submitted to surgery.
Search for other papers by Michela Perrino in
Google Scholar
PubMed
Search for other papers by Guia Vannucchi in
Google Scholar
PubMed
Search for other papers by Leonardo Vicentini in
Google Scholar
PubMed
Search for other papers by Gianmaria Cantoni in
Google Scholar
PubMed
Search for other papers by Davide Dazzi in
Google Scholar
PubMed
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Marcello Rodari in
Google Scholar
PubMed
Search for other papers by Arturo Chiti in
Google Scholar
PubMed
Search for other papers by Paolo Beck-Peccoz in
Google Scholar
PubMed
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
The incidence of papillary thyroid cancer (PTC) is rapidly growing, the recorded increase being mainly related to tumors ≤2 cm. The re-classification of tumors >1 and ≤2 cm limited to the thyroid from the T2 to the T1 category triggered some concerns about their best management. In order to identify possible predictors of disease outcome, several clinico-pathological features were analyzed by uni- and multivariate analyses in a retrospective consecutive series of 251 PTCs ≤2 cm. Moreover, since 37% of cases were submitted to prophylactic central compartment node dissection (CLND, VI–VII levels) and radioiodine ablation was performed only when the tumor had an extrathyroidal extension, the impact of these therapeutic tools on the final outcome was evaluated. Among all outcome predictors analyzed, only lymph node metastases and extracapsular invasion were strongly associated with persistence/recurrence. It is worth noting that neither age nor tumor size was a significant indicator of the outcome. Interestingly, as far as the therapeutic interventions are concerned, CLND was strongly associated with remission, whereas radioiodine ablation did not influence the outcome. In conclusion, present results confirm the prognostic influence of node metastases and extra-thyroidal invasion, indicating the need for aggressive treatment in tumors extending beyond the capsule. On the contrary, all pT1N0 tumors, regardless of the diameter, the number of intrathyroidal foci, and the age can be effectively treated only by surgery. The major impact of prophylactic CLND on prognosis suggests to routinely associate it to total thyroidectomy in cases with a preoperative diagnosis of malignancy.
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Search for other papers by Michela Perrino in
Google Scholar
PubMed
Search for other papers by Sara Badiali in
Google Scholar
PubMed
Search for other papers by Stefania Rossi in
Google Scholar
PubMed
Search for other papers by Valentina Cirello in
Google Scholar
PubMed
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Delfina Tosi in
Google Scholar
PubMed
Search for other papers by Gianmaria Cantoni in
Google Scholar
PubMed
Search for other papers by Luca Poggi in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, Endocrine Unit Fondazione IRCCS Ca' Granda, Endocrine Surgery Unit, Fondazione IRCCS Ca' Granda, Unit of Pathological Anatomy, Department of Health Science, University of Milan, Milan, Italy
Search for other papers by Gaetano Bulfamante in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, Endocrine Unit Fondazione IRCCS Ca' Granda, Endocrine Surgery Unit, Fondazione IRCCS Ca' Granda, Unit of Pathological Anatomy, Department of Health Science, University of Milan, Milan, Italy
Search for other papers by Paolo Beck-Peccoz in
Google Scholar
PubMed
Search for other papers by Leonardo Vicentini in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, Endocrine Unit Fondazione IRCCS Ca' Granda, Endocrine Surgery Unit, Fondazione IRCCS Ca' Granda, Unit of Pathological Anatomy, Department of Health Science, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Search for other papers by Paola Romeo in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Ital
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Roberta Granata in
Google Scholar
PubMed
Search for other papers by Giuseppina Calareso in
Google Scholar
PubMed
Search for other papers by Ambra Vittoria Gualeni in
Google Scholar
PubMed
Search for other papers by Matteo Dugo in
Google Scholar
PubMed
Search for other papers by Loris De Cecco in
Google Scholar
PubMed
Search for other papers by Maria Grazia Rizzetti in
Google Scholar
PubMed
Search for other papers by Angela Zanframundo in
Google Scholar
PubMed
Search for other papers by Antonella Aiello in
Google Scholar
PubMed
Search for other papers by Maria Luisa Carcangiu in
Google Scholar
PubMed
Search for other papers by Annunziata Gloghini in
Google Scholar
PubMed
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
Search for other papers by Stefano Ferrero in
Google Scholar
PubMed
Department of Medical Oncology, University of Milan, Milan, Italy
Search for other papers by Lisa Licitra in
Google Scholar
PubMed
Search for other papers by Angela Greco in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Ital
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Search for other papers by Laura Deborah Locati in
Google Scholar
PubMed
Search for other papers by Maria Grazia Borrello in
Google Scholar
PubMed
This study aimed to identify circulating miRNAs as novel non-invasive biomarkers for prognosis and vandetanib response in advanced medullary thyroid cancer (MTC) patients. We prospectively recruited two independent cohorts of locally advanced/metastatic MTC patients including a subgroup of vandetanib-treated subjects: a discovery cohort (n = 20), including matched plasma/tissue samples (n = 17/20), and a validation cohort, yielding only plasma samples (n = 17). Plasma samples from healthy subjects (n = 36) and MTC patients in remission (n = 9) were used as controls. MTC (n = 17 from 8 patients included in discovery cohort) and non-neoplastic thyroid specimens (n = 3) were assessed by microarray profiling to identify candidate circulating miRNAs. qRT-PCR and in situ hybridization were carried out to validate the expression and localization of a selected miRNA within tissues, and qRT-PCR was also performed to measure miRNA levels in plasma samples. By microarray analysis, we identified 51 miRNAs differentially expressed in MTC. The most overexpressed miR, miR-375, was highly expressed by C cells compared to other thyroid cells, and more expressed in MTC than in reactive C-cell hyperplasia. MTC patients had significantly higher miR-375 plasma levels than healthy controls (P < 0.0001) and subjects in remission (P = 0.0004) as demonstrated by qRT-PCR analysis. miR-375 plasma levels were not predictive of vandetanib response, but, notably, high levels were associated with significantly reduced overall survival (HR 10.61, P < 0.0001) and were a strong prognostic factor of poor prognosis (HR 6.24, P = 0.00025) in MTC patients. Overall, our results unveil plasma miR-375 as a promising prognostic marker for advanced MTC patients, to be validated in larger cohorts.
